Difference between revisions of "Ferumoxytol (Feraheme)"
m |
m |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. | + | Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b Ferumoxytol (Feraheme) package insert]</ref><ref>[[:File:Ferumoxytol.pdf | Ferumoxytol (Feraheme) package insert (locally hosted backup)]]</ref><ref>[https://www.feraheme.com/ Feraheme manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 22: | Line 22: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category:Iron]] | + | [[Category:Iron replacement]] |
[[Category:FDA approved in 2009]] | [[Category:FDA approved in 2009]] | ||
Latest revision as of 09:39, 1 July 2023
General information
Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Ferumoxytol (Feraheme) patient drug information[4]
- Ferumoxytol (Feraheme) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2009-06-30: Initial approval for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).
Also known as
- Brand name: Feraheme